When very positive safety and efficacy data appear from the completed Phase 3 Parkinson’s disease dementia and Alzheimer’s clinical trials, the entire investment community is going to say, “Well, Anavex will never be able to gain FDA approval for the drug because a bunch of message board people don’t like the guy.”